Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGSF22 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF22 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGSF21 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGSF21 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGSF21 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV5-52 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV5-52 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV5-52 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV7-43 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV7-43 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV7-43 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV7-46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV7-46 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV7-46 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV5-48 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV5-48 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV5-48 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV6-57 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV6-57 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV6-57 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV5-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV5-37 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV5-37 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV5-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV5-39 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV5-39 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV5-45 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV5-45 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV5-45 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV4-69 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV4-69 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV4-69 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →